For example, during neoadjuvant chemotherapy (doxorubicin/cyclophosphamide) in breast cancer patients, increased DUSP1 levels were associated with increased residual tumor burden post-chemotherapy.124. This evidence concerns the gene DUSP1 and breast carcinoma.